- Filter by
- Categories
- Tags
- Show all
- Article
- Confusion
- Contract
- Copyright
- Corporate
- Domain Names
- Employment
- Expungement
- Expungement
- Grey Marketing
- Industrial Designs
- Licensing
- Obviousness
- Opposition
- Passing Off
- Patent
- Patent Infringement
- Patent Strategy
- PM(NOC)
- Procedure
- Prosecution
- recognition
- Services
- Summary
- Trade Secrets
- Trade-mark
- Use
- Validity
- 35 US Code §101
- 3D printing
- Abandonment
- abstract theorems
- Abuse of Process
- Accounting of Profits
- acquired distinctiveness
- actions
- actual notice
- agreement
- Alice/Mayo Test
- Ambiguity
- Amendments
- Anticipation
- Appeal
- Apple
- application
- application fee
- arbitrary
- arbitration
- Artificial Intelligence
- Assignment
- Australia
- Bad Faith
- Bargain Theory
- Bill C-31
- Bill C-43
- Bill C-8
- Bill C-86
- Biologics
- biosimilar
- Biotech Patents
- Blockchain
- border measures
- Brand
- broadcasting
- budget
- burden of proof
- business
- CAFC
- Canada
- Canada Gazette
- Cannabis Law
- causal link
- cdrp
- CEEO
- Certificate of Supplementary Protection
- champerty
- Chemical Patent
- chemistry
- ciba
- CIPO
- CIPO errors
- CIRA
- Claim Construction
- Class Actions
- clerical error
- collateral estoppel
- College of Patent Agents and Trademark Agents
- combination drugs
- commissioner
- Common General Knowledge
- Complete Code
- Confidential Information
- confidentiality
- confidentiality order
- Conflict of Interest
- Confusion
- Constitution
- consumer goods
- contract
- contributory infringement
- Copyright
- Copyright Infringement
- copyright test
- corrections
- Costs
- counterfeit
- Court of Appeals for the Federal Circuit
- COVID-19
- CSP
- cybersecurity
- Damages
- Data
- Data Protection
- deadline
- defamation
- defences
- Delay to Market Entry
- descriptive
- Design Patents
- deviation
- digital infringement
- disclosure
- Discovery
- Distinctiveness
- Diversity
- division of powers
- divisionals
- DNA Patents
- domain names
- dominant feature
- Dosage Range
- Double Patenting
- doubtful cases
- Due Care
- Duty of Candor
- E-Commerce
- Early dismissal
- economics
- Employment
- errors
- essentiality of elements
- Ethics
- Europe
- Events
- Evidence
- examination quality
- examination statistics
- Examiner
- Expedited Examination
- Expert Blinding
- Expert Evidence
- expiry
- Expungement
- extraterritoriality
- Fair Use
- federal circuit
- Federal Court
- Federal Court of Appeal
- fees
- file wrapper
- Filing
- filing date
- filing fee
- financial services
- Food and Drug Regulations
- Foreign Filing License
- foreign issue estoppel
- forum selection
- fraud
- Free World Trust
- frivolous
- funding
- future infringement
- generics
- geographical indications
- Good Faith
- goods
- Government
- Grace Period
- grey marketing
- Hague
- Hatch-Waxman
- Health Canada
- Hearsay
- Honest Contractual Performance
- ICSID
- Illegality
- Improver
- Indefiniteness
- Inducement
- Industrial Designs
- inherent distinctiveness
- Injunction
- Injunctions
- Innovation
- Innovative Drugs
- Insufficient Disclosure
- Intellectual Property
- intent
- Inter Partes Review
- interlocutory injunction
- Internet
- Internship
- intra vires
- Investors
- IP Lawyer
- IP Strategy
- IPIC
- IPO
- ISP
- IT patent
- ITC
- Jurisdiction
- Late fee
- Legal Retainer
- legal test
- Legislative Reform
- Liability
- Licensing
- life science
- limitation periods
- Litigation
- litigation funding agreement
- Madrid Protocol
- Maintenance Fee
- Marking Requirement
- materiality
- medical
- method
- Methods of Medical Treatment
- misleading
- motion
- Motion to dismiss
- Motion to strike
- NAFTA
- national phase entry
- Natural Health Product
- new evidence
- Non-Infringing Alternative
- Non-Practicing Entity
- notice of allegation
- notice to rectify
- Novelty
- obivous error
- Obviousness
- Official Marks
- On-Sale Bar
- ontario
- Overbreadth
- Ownership & Inventorship
- Passing Off
- Patent Act
- Patent Agents
- Patent Appeal Board
- Patent Application
- Patent Drafting
- Patent Infringement
- Patent Litigation
- Patent Office
- patent office errors
- patent practicioner
- patent prosecution
- patent requirement
- Patent Rules
- Patent Strategy
- Patent Term Adjustment
- Patent Textbook
- Patent Trial and Appeal Board
- Patent Trolls
- patentability
- Patentable Subject Matter
- Patents
- PCT
- Pharmaceutical Patent
- Pharmaceutical Pricing
- PLT
- PM(NOC)
- PM(NOC) Damages
- PMPRB
- POSITA
- pride
- prior art
- Prior Disclosure
- prior use
- Priority
- Privilege
- procedure
- Product Specificity
- prohibited marks
- Promise Doctrine
- proprietor
- Prosecution
- Prosecution History
- protective order
- prothonotaries
- Provisional Patent
- public sale
- Public Servant
- Punitive Damages
- Recognition
- Records
- registration
- Reinstatement
- Reissue
- Remedies
- representation
- request for correction
- requisition
- responding
- review
- risk
- Royalties
- s. 27
- s. 45
- s. 53
- sale
- Scheduling
- Scholarship
- SCOTUS
- second person
- Secondary Infringement
- secondary meaning
- secret sale
- section 28
- Section 45
- section 50
- Section 52
- section 56
- section 7
- security
- Selection Patents
- Services
- settlement
- Site-Blocking Orders
- skilled person
- Software
- Software Copyright
- Software Patent
- Sound Prediction
- Specification
- sponsorship
- Springboard Profits
- SRED
- Standard of Proof
- Standard of Review
- Standard-Essential Patents
- standing
- standing to appeal
- Start-up
- Startups
- Statute of Monopolies
- stay
- Strategy
- Sufficiency
- Summary Judgment
- superior court
- Supreme Court of Canada
- surname
- Technology
- Telecommunications
- time frame
- TPP
- Trade Secrets
- Trade-Mark
- Trademark
- Trademark Infringement
- Trademark Licensing
- Trademark Opposition
- Trademark Trial and Appeal Board
- Trademarks Act
- treaty
- UK
- United Kingdom
- United States
- Use
- useful article
- USMCA
- USPTO
- Utility
- Validity
- Variant
- Varying records
- Velocity
- vexatious
- who's who legal
- Written Description
January 6, 2014
January 6, 2014
Allergan Inc. v Canada (Health), [2013 FC 1165] Background The decision is related to a motion pursuant to Rule 312 of the Federal Courts Rules […]
December 23, 2013
December 23, 2013
Re. Patent Application 2,333,184 CD 1345 Background The patent application at issue is for an automated method of classifying or sorting plant embryos of […]
December 23, 2013
December 23, 2013
Re. Patent Application 2,223,198 CD 1344 Background Patent application 2,223,198 is for a nutritional composition that has successfully caused Chrohn’s disease to go into […]
December 23, 2013
December 23, 2013
Re. Application 2,365,923 CD 1343 Background The Application is for a patent for the use of a drug to treat patients suffering from a rare genetic […]
December 23, 2013
December 23, 2013
Re: Patent Application 2,237,960 CD 1342 Background The application relates to the manufacture of precipitated calcium carbonate from impure calcium oxide. On 17th of […]
December 23, 2013
December 23, 2013
Apotex Inc. v Takeda Canada Inc. 2013 FC 1237 Background This is an application under section 8 of the PM(NOC) process dealing with lost revenue […]
November 28, 2013
November 28, 2013
Apotex Inc. v. H. Lundbeck A/S [2013 FC 1188] Background Apotex was the losing party in an impeachment trial of Lundbeck’s Canadian Patent 1,339,452 in which Lundbeck […]
November 26, 2013
November 26, 2013
Bell Helicopter Textron Canada Limitee v Eurocopter, 2013 FCA 261 Background The Federal Court of Appeal declined a motion under Rule 397 of the Federal Court […]
November 7, 2013
November 7, 2013
SEC Filing Background Twitter’s SEC filing for their initial public offering (IPO) were recently released. Within the filing there are several interesting issues related to their […]
October 31, 2013
October 31, 2013
Background The Federal Government has recently tabled Bill C-8 entitled An Act to amend the Copyright Act and the Trade-marks Act and to make consequential amendments […]
October 29, 2013
October 29, 2013
Teva Canada Limited v Pfizer Canada Inc. [2013 FC 1066] Background The present action is pursuant to s. 8 of the PM(NOC) Regulations for damages […]
October 29, 2013
October 29, 2013
Bayer Inc. v Cobalt Pharmaceuticals Company [2013 FC 1061] Background This proceeding is an application under the NOC regulations by Bayer seeking a prohibition order to […]
October 24, 2013
October 24, 2013
Summary Canada and the EU have signed a Comprehensive Economic and Trade Agreement (CETA). The agreement includes potential changes to the Canadian pharmaceutical industry. The most […]
October 24, 2013
October 24, 2013
Summary A new bill (H.R. 3309) was introduced entitled The Innovation Act of 2013. The bill is cosponsored by Howard Coble (R-N.C.) the chairman of the […]
October 24, 2013
October 24, 2013
Mylan Pharmaceuticals ULC v Bristol-Myers Squibb Canada Co. [2013 FCA 231] Background This is an appeal of a cost award from a Judgment of Justice Barnes […]
October 22, 2013
October 22, 2013
Pfizer Canada Inc. v Apotex Inc., [2013 FC 1036] Background This is a decision of Prothonotary Aalto dealing with the consequence of a reversal order. […]
October 18, 2013
October 18, 2013
Teva Canada Limited v Novartis Pharmaceuticals Canada Inc, 2013 FCA 244. Background Teva appealed a judgment of Justice Hughes(2012 FC 283) where a prohibition order was […]
October 18, 2013
October 18, 2013
F Hoffmann-La Roche AG v Commissioner of Patents, 2013 FC 1001. Background This is an application for an order pursuant to s. 20 of the […]
October 18, 2013
October 18, 2013
Distrimedic Inc v Dispill Inc. 2013 FC 1043 Background The patent at issue is Canadian Patent No. 2,207,045. The product is a kit for the manufacture […]
October 8, 2013
October 8, 2013
Novartis Pharmaceuticals Canada Inc. v Cobalt Pharmaceuticals Company [2013 FC 985] Affirmed on Appeal [2014 FCA 17] Background This is an application under the NOC regulations […]